We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52‐week open‐label, randomized phase III trial
Once-weekly dulaglutide versus insulin glargine for type 2 diabetes in mostly Asian patients taking metformin or sulphonylurea: 52-week safety and effectiveness
AI simplified
Abstract
A total of 774 patients were enrolled in a 52-week study comparing dulaglutide to insulin glargine for type 2 diabetes management.
- Dulaglutide 1.5 mg showed a mean reduction in HbA1c of -18.9 mmol/mol (-1.73%) at 26 weeks, which was superior to the -12.7 mmol/mol (-1.16%) reduction with glargine.
- More patients achieved an HbA1c target of <53.0 mmol/mol (<7.0%) with dulaglutide 1.5 mg and 0.75 mg compared to glargine.
- Body weight decreased with dulaglutide treatment, while it increased with insulin glargine.
- The incidence of total hypoglycaemia was lower in patients receiving dulaglutide compared to those on glargine.
- Gastrointestinal issues, such as diarrhoea and nausea, were the most common adverse events associated with dulaglutide.
AI simplified
Key numbers
-18.9 (0.73) mmol/mol (-1.73 [0.067]%)
HbA1c Change (Dulaglutide 1.5 mg)
Change from baseline at week 26 for dulaglutide 1.5 mg.
64.8%
HbA1c Target Achievement
Percentage of patients achieving HbA1c <53.0 mmol/mol at week 26.
-1.47 (0.197) kg
Weight Change (Dulaglutide 1.5 mg)
Change from baseline at week 26 for dulaglutide 1.5 mg.